Sepsis & infection

Aspiration pneumonia in the world's most aged society: age-stratified ICU management and outcomes from a nationwide Japanese registry

J Intensive CarePublished Retrospective cohort study

Authors' conclusion

Older patients with aspiration pneumonia had higher illness severity yet received less MV, and had higher in-hospital mortality and lower home discharge rates.

Study context

Population
Adults ≥ 18 years admitted to Japanese ICUs with a primary diagnosis of aspiration pneumonia, JIPAD registry, 2015–2023
Participants
3,906 eligible ICU admissions
Exposure
Age groups 18-64, 65-74, 75-84 and ≥ 85 years
Outcome
In-hospital mortality
Methodological detailsmulticentre, observational, nationwide registry
  • Multicentre
  • Observational
  • Nationwide registry

Main finding

As reported in the abstract

Overall in-hospital mortality
28.3%

Observational data: associations, not effects.

Further findings

Invasive MV use

Outcome18-64 years65-74 years75-84 years≥ 85 years
Home discharge45.2%— not stated in the abstract— not stated in the abstract19.9%
Illness severity at admission (APACHE III score)Median74 (IQR 56–91)— not stated in the abstract— not stated in the abstract96 (IQR 81–120)

— not stated in the abstract

Invasive mechanical ventilation (MV) use — Overall invasive MV use
68.8%

Invasive MV use

Probability of MV use decreased with age, particularly > 75 years (exploratory adjusted analyses)

Hospital and ICU LOS (overall)

Median hospital LOS 32 days (IQR, 16-58)
32
Median ICU LOS 120.4 h (IQR, 54.4-234.8)

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Aspiration pneumonia in the world's most aged society: age-stratified ICU management and outcomes from a nationwide Japanese registry. J Intensive Care. Published 1 August 2026. doi:10.1186/s40560-026-00923-1

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.